More on LRMR
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $6.46 |
|
|||
| Open | $6.46 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $6.46 | ||||
| Day Low | $6.46 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,522 | ||||
- Form PRE 14A Larimar Therapeutics, For: May 29
- Leerink Partners Starts Larimar Therapeutics (LRMR) at Outperform
- Form SC 13D/A Larimar Therapeutics, Filed by: Flynn James E
- Form S-8 Larimar Therapeutics,
- Form S-8 Larimar Therapeutics,
- Form 10-K Larimar Therapeutics, For: Dec 31
- Form 8-K Larimar Therapeutics, For: Mar 14
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
- Form 8-K Larimar Therapeutics, For: Mar 11
- Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
Entities mentioned with LRMR
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Guggenheim | View Related Stories »
- Deerfield Management | View Related Stories »
- S3 | View Related Stories »
- RA Capital | View Related Stories »
- 13D | View Related Stories »
- Show More...
